Icon
+91 94997 68112
Login Register

Ravicti - (1.1 gm/ml; Liquid, Oral)

Glycerol Phenylbutyrate Horizon Pharma
1.1 gm/ml; Liquid, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None None
Indicated for use as a nitrogen-binding agent for chronic management of adult and pediatric patients ≥ 2 years of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone
Yes
*** ** *** ***** ** **** **** ** **** ******* '*** *** *, ****, '*** *** **, **** *** *** ************ *********. ****** *** ****** ** ** ******, ******* ******* *** **** ***** *** ********* ** ****** ** *******. ***** ****** ** *** ** ****. ********* *** ***** *** ** ***** ****** ****** *** *** **** ******* ** ****, ***** *** **** ***** *** ******* ** *****. ***** ***** ***** **** ** **** **** ******* ** *** *** *** ************ *********. *** & ***** ***** *** *********** ****** ** *** **** *** ******* ** ******* ***. '***, '***, '*** (*** ***** ******** ** *** *, ****) *** **** ***** ****** '*** ** ******* ******* ** *** ***** *** ******* ** *******. ******* ********** **** ***** *** ******* ********* ** *** ***** ** ***** ***** *** ****** *** ******* ** **** *, ****. ********** *** ******* **** ***. ********* ** *** ***** ** ***** *** *** ****** *** ******* ** **** *, ****. ********* ** ********** **** ***** *** ****** (******), **** ********* *** ****** ***** ******* ** *** *, ****.
Ravicti Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13 Patent 14 Patent 15 Patent 16
*** ****** ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* *** ********* (***** ******)
***** ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* *** ********* (***** ******)
*** (****) ******* ******* ******* ******* ******* ******* ******* *** ********* ******* *** ********* ******* ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
*** ****** *** \ *** *** **, **** ******* ******** ************ ** **** *, ****
***** ** \ ** ***** **, **** ******* **** ** **** *, ****
*** (****) ** \ ** *** *, **** ******* **** ******* *** **** *** *** ****
  1. *** **, **** : *** ******** ******* ***** *** **** ** **** ******* '*** *** *, ****, '*** *** **, ****.
  2. *** **, **** : ******* ***** * **** ******* *** ******** ***** *** *** ******* ******** ** ***** ******** ********.
  3. *** **, **** : *** ***** *** ** ***** ****** ****** ** ****** '*** *** *, ****, '*** *** **, **** ** ****.
  4. *** *, **** : ***** ******** ******* ***** *** **** ** **** ******* '*** *** *, ****, '*** *** **, ****.
  5. *** **, **** : ******* ***** * **** ******* ***** ** ******** ***** ** **.
  6. *** *, **** : **** ***** *** ******* '*** *** *, ****, '*** *** **, **** ** *****.
  7. *** **, **** : **** ******** *** ********* ****** ** **** *** **** ******* **** **** ******* ** ****** '***.
  8. *** **, **** : ***** & *** ******** ** **** *** *********** ****** ** ******* '***, '*** **** ******** ** ***** *, ****.
  9. *** **, **** : **** ***** ****** '*** (*** *, ****) ** *******. *** ********** *** ********* **** **** *** *******.
  10. *** **, **** : **** ***** ** ******* *** *********** ****** *** ****** '*** (***** *, ****).
  11. *** **, **** : ********** ********* **** ***** *** *** *** ******* ** **** ** **** ******** ***** & ****. ********* ** *** ***** ** ***** ***** *** ****** *** ******* ** **** *, ****.
  12. *** *, **** : ********** ********* **** *** *** *** *** ******* ** **** ** **** ******** ***** & ****, ******* ****** ***** **** ******* ***** * *** **** ******* *** *** **** ****** '***(**** **, ****).********* ** *** ***** ** ***** *** *** ****** *** ******* ** **** *, ****
  13. *** *, **** : *** *** ********** **** ****** '***(**** **, ****) ********* **** ***.
  14. *** *, **** : **** ******** ******* ***** *** ****-** ******.
  15. *** **, **** : ******* **** **** **** ************ ** ******* '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, *** '***.
  16. *** **, **** : ******* *** **** ******* ********* **********. ** ****** ** *** * **********.
  17. *** **, **** : **** ******** ******* ***** *** **** ** ******.
  18. *** *, **** : ******* **** **** **** ************ ** ****** ** '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, '***, *** '***.
  19. *** *, **** : ******* ********* ********** ******* **** **** ************ ** *** *******. **, ****** ** ** ** **********.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.